Madhu Natarajan

Madhu Natarajan currently serves as the Chief Executive Officer of Crosswalk Therapeutics, focusing on rare diseases and advocating for drug invention. Previous roles include serving as a Scientific Advisory Board Member and Consultant with Invetx, and holding various leadership positions at Takeda and Shire, emphasizing research in rare genetic diseases and preclinical portfolio strategies. Madhu Natarajan has also contributed to academia as an Adjunct Faculty member at Brandeis University and as an Assistant Professor at the University of Texas Southwestern Medical Center, along with experience in product design at Physiome Sciences and as a Principal Scientist at Pfizer. Academic qualifications include a Ph.D. in Neurobiology from Northwestern University, a B.E. in Electronics & Communication Engineering from the University of Madras, and additional education from The University of Akron.